Search Results

The life science group Sartorius announced that, through its subgroup Sartorius Stedim Biotech, it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission.

Sartorius Stedim Biotech, a leading partner of the biopharma industry, announced that it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission.

Thermo Fisher Scientific Inc., (NYSE: TMO), the world leader in serving science, and Groupe Novasep SAS (Novasep), a leading supplier of services and technologies for the life sciences industry, today announced it has completed the acquisition of Henogen S.A.

The life science company Sartorius announced it has entered into an agreement through its subgroup Sartorius Stedim Biotech to acquire the chromatography process equipment division of Novasep.

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, announced it has entered into an agreement to acquire the chromatography process equipment division of Novasep.

Sensorion and Novasep announce the signature of an agreement for the manufacturing of adeno-associated virus vectors.

PharmaZell, the German producer of highly resilient and specialty APIs, and France-based Novasep, a leading CDMO focused on complex small molecules and ADCs have entered into exclusive negotiations to create a leading European platform in the attractive API manufacturing and CDMO space with a complementary set of differentiated technologies and highly diversified base of blue-chip pharma and biotech customers.

Novasep, a leading supplier of services and technologies for the life sciences industry, introduces the new Biopharma Solutions Business Unit, led by Cédric Volanti.

Novasep announced the signature of an agreement for the development and manufacturing of LYS-GM101, an AAVrh10-based gene therapy drug candidate for the treatment of GM1 Gangliosidosis, a rare neuronopathic lysosomal storage disorder.

Leveraging on its recent investments Senrise-IV and Senefill, Novasep launches a unique 2-year turnkey plant offer to accelerate commercial production of viral vectors.